HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM) Stock Competitors & Peer Comparison
See HTGM's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Medical - Diagnostics & Research Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for HTGM and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| HTGM | $0.48 | +0.00% | 1.1M | -0.03 | -$17.10 | N/A |
| DHR-PB | $1,261.26 | -0.78% | 916.8B | 146.01 | $8.64 | +0.64% |
| TMO | $679.61 | +0.15% | 251.3B | 29.34 | $23.16 | +0.27% |
| DHR | $226.11 | -0.54% | 159B | 28.35 | $7.98 | +0.64% |
| NTRA | $414.52 | +0.67% | 59.4B | -314.03 | -$1.32 | N/A |
| A | $175.03 | -0.10% | 49.4B | 30.12 | $5.81 | +0.58% |
| IQV | $268.99 | -0.73% | 44.3B | 22.19 | $12.13 | N/A |
| WAT | $443.26 | +0.07% | 43.5B | 32.42 | $13.68 | N/A |
| IDXX | $533.44 | +0.83% | 42.1B | 37.51 | $14.22 | N/A |
| ILMN | $272.00 | +0.04% | 41.2B | 54.08 | $5.03 | N/A |
Stock Comparison
Danaher Corporation (NYSE: DHR-PB)
HTGM vs DHR-PB Comparison September 2026
HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HTGM stands at 1.1M. In comparison, DHR-PB has a market cap of 916.8B. Regarding current trading prices, HTGM is priced at $0.48 on the NASDAQ, while DHR-PB trades at $1,261.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HTGM currently has a P/E ratio of -0.03, whereas DHR-PB's P/E ratio is 146.01. In terms of profitability, HTGM's ROE is -2.73%, compared to DHR-PB's ROE of +0.08%. Regarding short-term risk, HTGM is less volatile compared to DHR-PB. This indicates lower risk in terms of short-term price fluctuations for HTGM.Check DHR-PB's competition here
Thermo Fisher Scientific Inc. (NYSE: TMO)
HTGM vs TMO Comparison September 2026
HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HTGM stands at 1.1M. In comparison, TMO has a market cap of 251.3B. Regarding current trading prices, HTGM is priced at $0.48 on the NASDAQ, while TMO trades at $679.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HTGM currently has a P/E ratio of -0.03, whereas TMO's P/E ratio is 29.34. In terms of profitability, HTGM's ROE is -2.73%, compared to TMO's ROE of +0.13%. Regarding short-term risk, HTGM is less volatile compared to TMO. This indicates lower risk in terms of short-term price fluctuations for HTGM.Check TMO's competition here
Danaher Corporation (NYSE: DHR)
HTGM vs DHR Comparison September 2026
HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HTGM stands at 1.1M. In comparison, DHR has a market cap of 159B. Regarding current trading prices, HTGM is priced at $0.48 on the NASDAQ, while DHR trades at $226.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HTGM currently has a P/E ratio of -0.03, whereas DHR's P/E ratio is 28.35. In terms of profitability, HTGM's ROE is -2.73%, compared to DHR's ROE of +0.08%. Regarding short-term risk, HTGM is less volatile compared to DHR. This indicates lower risk in terms of short-term price fluctuations for HTGM.Check DHR's competition here
Natera, Inc. (NASDAQ: NTRA)
HTGM vs NTRA Comparison September 2026
HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HTGM stands at 1.1M. In comparison, NTRA has a market cap of 59.4B. Regarding current trading prices, HTGM is priced at $0.48 on the NASDAQ, while NTRA trades at $414.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HTGM currently has a P/E ratio of -0.03, whereas NTRA's P/E ratio is -314.03. In terms of profitability, HTGM's ROE is -2.73%, compared to NTRA's ROE of -0.12%. Regarding short-term risk, HTGM is less volatile compared to NTRA. This indicates lower risk in terms of short-term price fluctuations for HTGM.Check NTRA's competition here
Agilent Technologies, Inc. (NYSE: A)
HTGM vs A Comparison September 2026
HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HTGM stands at 1.1M. In comparison, A has a market cap of 49.4B. Regarding current trading prices, HTGM is priced at $0.48 on the NASDAQ, while A trades at $175.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HTGM currently has a P/E ratio of -0.03, whereas A's P/E ratio is 30.12. In terms of profitability, HTGM's ROE is -2.73%, compared to A's ROE of +0.20%. Regarding short-term risk, HTGM is less volatile compared to A. This indicates lower risk in terms of short-term price fluctuations for HTGM.Check A's competition here
IQVIA Holdings Inc. (NYSE: IQV)
HTGM vs IQV Comparison September 2026
HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HTGM stands at 1.1M. In comparison, IQV has a market cap of 44.3B. Regarding current trading prices, HTGM is priced at $0.48 on the NASDAQ, while IQV trades at $268.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HTGM currently has a P/E ratio of -0.03, whereas IQV's P/E ratio is 22.19. In terms of profitability, HTGM's ROE is -2.73%, compared to IQV's ROE of +0.22%. Regarding short-term risk, HTGM is less volatile compared to IQV. This indicates lower risk in terms of short-term price fluctuations for HTGM.Check IQV's competition here
Waters Corporation (NYSE: WAT)
HTGM vs WAT Comparison September 2026
HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HTGM stands at 1.1M. In comparison, WAT has a market cap of 43.5B. Regarding current trading prices, HTGM is priced at $0.48 on the NASDAQ, while WAT trades at $443.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HTGM currently has a P/E ratio of -0.03, whereas WAT's P/E ratio is 32.42. In terms of profitability, HTGM's ROE is -2.73%, compared to WAT's ROE of +0.02%. Regarding short-term risk, HTGM is less volatile compared to WAT. This indicates lower risk in terms of short-term price fluctuations for HTGM.Check WAT's competition here
IDEXX Laboratories, Inc. (NASDAQ: IDXX)
HTGM vs IDXX Comparison September 2026
HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HTGM stands at 1.1M. In comparison, IDXX has a market cap of 42.1B. Regarding current trading prices, HTGM is priced at $0.48 on the NASDAQ, while IDXX trades at $533.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HTGM currently has a P/E ratio of -0.03, whereas IDXX's P/E ratio is 37.51. In terms of profitability, HTGM's ROE is -2.73%, compared to IDXX's ROE of +0.72%. Regarding short-term risk, HTGM is less volatile compared to IDXX. This indicates lower risk in terms of short-term price fluctuations for HTGM.Check IDXX's competition here
Illumina, Inc. (NASDAQ: ILMN)
HTGM vs ILMN Comparison September 2026
HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HTGM stands at 1.1M. In comparison, ILMN has a market cap of 41.2B. Regarding current trading prices, HTGM is priced at $0.48 on the NASDAQ, while ILMN trades at $272.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HTGM currently has a P/E ratio of -0.03, whereas ILMN's P/E ratio is 54.08. In terms of profitability, HTGM's ROE is -2.73%, compared to ILMN's ROE of +0.31%. Regarding short-term risk, HTGM is less volatile compared to ILMN. This indicates lower risk in terms of short-term price fluctuations for HTGM.Check ILMN's competition here
Mettler-Toledo International Inc. (NYSE: MTD)
HTGM vs MTD Comparison September 2026
HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HTGM stands at 1.1M. In comparison, MTD has a market cap of 31.1B. Regarding current trading prices, HTGM is priced at $0.48 on the NASDAQ, while MTD trades at $1,537.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HTGM currently has a P/E ratio of -0.03, whereas MTD's P/E ratio is 35.36. In terms of profitability, HTGM's ROE is -2.73%, compared to MTD's ROE of -12.00%. Regarding short-term risk, HTGM is less volatile compared to MTD. This indicates lower risk in terms of short-term price fluctuations for HTGM.Check MTD's competition here
Quest Diagnostics Incorporated (NYSE: DGX)
HTGM vs DGX Comparison September 2026
HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HTGM stands at 1.1M. In comparison, DGX has a market cap of 25.6B. Regarding current trading prices, HTGM is priced at $0.48 on the NASDAQ, while DGX trades at $231.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HTGM currently has a P/E ratio of -0.03, whereas DGX's P/E ratio is 22.87. In terms of profitability, HTGM's ROE is -2.73%, compared to DGX's ROE of +0.14%. Regarding short-term risk, HTGM is less volatile compared to DGX. This indicates lower risk in terms of short-term price fluctuations for HTGM.Check DGX's competition here
Labcorp Holdings Inc. (NYSE: LH)
HTGM vs LH Comparison September 2026
HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HTGM stands at 1.1M. In comparison, LH has a market cap of 25.3B. Regarding current trading prices, HTGM is priced at $0.48 on the NASDAQ, while LH trades at $308.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HTGM currently has a P/E ratio of -0.03, whereas LH's P/E ratio is 18.33. In terms of profitability, HTGM's ROE is -2.73%, compared to LH's ROE of +0.12%. Regarding short-term risk, HTGM is less volatile compared to LH. This indicates lower risk in terms of short-term price fluctuations for HTGM.Check LH's competition here
Guardant Health, Inc. (NASDAQ: GH)
HTGM vs GH Comparison September 2026
HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HTGM stands at 1.1M. In comparison, GH has a market cap of 23.9B. Regarding current trading prices, HTGM is priced at $0.48 on the NASDAQ, while GH trades at $177.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HTGM currently has a P/E ratio of -0.03, whereas GH's P/E ratio is -50.93. In terms of profitability, HTGM's ROE is -2.73%, compared to GH's ROE of +2.11%. Regarding short-term risk, HTGM is less volatile compared to GH. This indicates lower risk in terms of short-term price fluctuations for HTGM.Check GH's competition here
Exact Sciences Corporation (NASDAQ: EXAS)
HTGM vs EXAS Comparison September 2026
HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HTGM stands at 1.1M. In comparison, EXAS has a market cap of 20B. Regarding current trading prices, HTGM is priced at $0.48 on the NASDAQ, while EXAS trades at $104.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HTGM currently has a P/E ratio of -0.03, whereas EXAS's P/E ratio is -95.37. In terms of profitability, HTGM's ROE is -2.73%, compared to EXAS's ROE of -0.09%. Regarding short-term risk, HTGM is similarly volatile compared to EXAS. This indicates similar risk in terms of short-term price fluctuations for HTGM.Check EXAS's competition here
Medpace Holdings, Inc. (NASDAQ: MEDP)
HTGM vs MEDP Comparison September 2026
HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HTGM stands at 1.1M. In comparison, MEDP has a market cap of 17.4B. Regarding current trading prices, HTGM is priced at $0.48 on the NASDAQ, while MEDP trades at $622.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HTGM currently has a P/E ratio of -0.03, whereas MEDP's P/E ratio is 36.47. In terms of profitability, HTGM's ROE is -2.73%, compared to MEDP's ROE of +1.10%. Regarding short-term risk, HTGM is less volatile compared to MEDP. This indicates lower risk in terms of short-term price fluctuations for HTGM.Check MEDP's competition here
Revvity, Inc. (NYSE: RVTY)
HTGM vs RVTY Comparison September 2026
HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HTGM stands at 1.1M. In comparison, RVTY has a market cap of 17B. Regarding current trading prices, HTGM is priced at $0.48 on the NASDAQ, while RVTY trades at $152.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HTGM currently has a P/E ratio of -0.03, whereas RVTY's P/E ratio is 28.55. In terms of profitability, HTGM's ROE is -2.73%, compared to RVTY's ROE of +0.03%. Regarding short-term risk, HTGM is less volatile compared to RVTY. This indicates lower risk in terms of short-term price fluctuations for HTGM.Check RVTY's competition here
Illumina, Inc. Common Stock Ex-distribution When-Issued (NASDAQ: ILMNV)
HTGM vs ILMNV Comparison September 2026
HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HTGM stands at 1.1M. In comparison, ILMNV has a market cap of 17B. Regarding current trading prices, HTGM is priced at $0.48 on the NASDAQ, while ILMNV trades at $107.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HTGM currently has a P/E ratio of -0.03, whereas ILMNV's P/E ratio is N/A. In terms of profitability, HTGM's ROE is -2.73%, compared to ILMNV's ROE of N/A. Regarding short-term risk, HTGM is similarly volatile compared to ILMNV. This indicates similar risk in terms of short-term price fluctuations for HTGM.Check ILMNV's competition here
PerkinElmer, Inc. (NYSE: PKI)
HTGM vs PKI Comparison September 2026
HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HTGM stands at 1.1M. In comparison, PKI has a market cap of 14.5B. Regarding current trading prices, HTGM is priced at $0.48 on the NASDAQ, while PKI trades at $115.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HTGM currently has a P/E ratio of -0.03, whereas PKI's P/E ratio is 41.45. In terms of profitability, HTGM's ROE is -2.73%, compared to PKI's ROE of +0.03%. Regarding short-term risk, HTGM is less volatile compared to PKI. This indicates lower risk in terms of short-term price fluctuations for HTGM.Check PKI's competition here
Charles River Laboratories International, Inc. (NYSE: CRL)
HTGM vs CRL Comparison September 2026
HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HTGM stands at 1.1M. In comparison, CRL has a market cap of 14.3B. Regarding current trading prices, HTGM is priced at $0.48 on the NASDAQ, while CRL trades at $295.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HTGM currently has a P/E ratio of -0.03, whereas CRL's P/E ratio is 29.91. In terms of profitability, HTGM's ROE is -2.73%, compared to CRL's ROE of -0.08%. Regarding short-term risk, HTGM is less volatile compared to CRL. This indicates lower risk in terms of short-term price fluctuations for HTGM.Check CRL's competition here
ICON Public Limited Company (NASDAQ: ICLR)
HTGM vs ICLR Comparison September 2026
HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HTGM stands at 1.1M. In comparison, ICLR has a market cap of 13B. Regarding current trading prices, HTGM is priced at $0.48 on the NASDAQ, while ICLR trades at $170.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HTGM currently has a P/E ratio of -0.03, whereas ICLR's P/E ratio is 13.89. In terms of profitability, HTGM's ROE is -2.73%, compared to ICLR's ROE of +0.04%. Regarding short-term risk, HTGM is less volatile compared to ICLR. This indicates lower risk in terms of short-term price fluctuations for HTGM.Check ICLR's competition here
Qiagen N.V. (NYSE: QGEN)
HTGM vs QGEN Comparison September 2026
HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HTGM stands at 1.1M. In comparison, QGEN has a market cap of 9.2B. Regarding current trading prices, HTGM is priced at $0.48 on the NASDAQ, while QGEN trades at $44.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HTGM currently has a P/E ratio of -0.03, whereas QGEN's P/E ratio is 18.34. In terms of profitability, HTGM's ROE is -2.73%, compared to QGEN's ROE of +0.12%. Regarding short-term risk, HTGM is less volatile compared to QGEN. This indicates lower risk in terms of short-term price fluctuations for HTGM.Check QGEN's competition here
GRAIL Inc. (NASDAQ: GRAL)
HTGM vs GRAL Comparison September 2026
HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HTGM stands at 1.1M. In comparison, GRAL has a market cap of 5.9B. Regarding current trading prices, HTGM is priced at $0.48 on the NASDAQ, while GRAL trades at $136.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HTGM currently has a P/E ratio of -0.03, whereas GRAL's P/E ratio is -14.01. In terms of profitability, HTGM's ROE is -2.73%, compared to GRAL's ROE of -0.16%. Regarding short-term risk, HTGM is less volatile compared to GRAL. This indicates lower risk in terms of short-term price fluctuations for HTGM.Check GRAL's competition here
RadNet, Inc. (NASDAQ: RDNT)
HTGM vs RDNT Comparison September 2026
HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HTGM stands at 1.1M. In comparison, RDNT has a market cap of 5.6B. Regarding current trading prices, HTGM is priced at $0.48 on the NASDAQ, while RDNT trades at $70.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HTGM currently has a P/E ratio of -0.03, whereas RDNT's P/E ratio is 153.59. In terms of profitability, HTGM's ROE is -2.73%, compared to RDNT's ROE of -0.02%. Regarding short-term risk, HTGM is less volatile compared to RDNT. This indicates lower risk in terms of short-term price fluctuations for HTGM.Check RDNT's competition here
BillionToOne, Inc. (NASDAQ: BLLN)
HTGM vs BLLN Comparison September 2026
HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HTGM stands at 1.1M. In comparison, BLLN has a market cap of 5.4B. Regarding current trading prices, HTGM is priced at $0.48 on the NASDAQ, while BLLN trades at $118.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HTGM currently has a P/E ratio of -0.03, whereas BLLN's P/E ratio is 168.83. In terms of profitability, HTGM's ROE is -2.73%, compared to BLLN's ROE of +0.08%. Regarding short-term risk, HTGM is less volatile compared to BLLN. This indicates lower risk in terms of short-term price fluctuations for HTGM.Check BLLN's competition here
Sotera Health Company (NASDAQ: SHC)
HTGM vs SHC Comparison September 2026
HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HTGM stands at 1.1M. In comparison, SHC has a market cap of 5.3B. Regarding current trading prices, HTGM is priced at $0.48 on the NASDAQ, while SHC trades at $18.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HTGM currently has a P/E ratio of -0.03, whereas SHC's P/E ratio is 19.38. In terms of profitability, HTGM's ROE is -2.73%, compared to SHC's ROE of +0.27%. Regarding short-term risk, HTGM is less volatile compared to SHC. This indicates lower risk in terms of short-term price fluctuations for HTGM.Check SHC's competition here
Syneos Health, Inc. (NASDAQ: SYNH)
HTGM vs SYNH Comparison September 2026
HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HTGM stands at 1.1M. In comparison, SYNH has a market cap of 4.5B. Regarding current trading prices, HTGM is priced at $0.48 on the NASDAQ, while SYNH trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HTGM currently has a P/E ratio of -0.03, whereas SYNH's P/E ratio is 61.40. In terms of profitability, HTGM's ROE is -2.73%, compared to SYNH's ROE of +0.08%. Regarding short-term risk, HTGM is less volatile compared to SYNH. This indicates lower risk in terms of short-term price fluctuations for HTGM.Check SYNH's competition here
Veracyte, Inc. (NASDAQ: VCYT)
HTGM vs VCYT Comparison September 2026
HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HTGM stands at 1.1M. In comparison, VCYT has a market cap of 3.7B. Regarding current trading prices, HTGM is priced at $0.48 on the NASDAQ, while VCYT trades at $46.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HTGM currently has a P/E ratio of -0.03, whereas VCYT's P/E ratio is 23.04. In terms of profitability, HTGM's ROE is -2.73%, compared to VCYT's ROE of +0.09%. Regarding short-term risk, HTGM is less volatile compared to VCYT. This indicates lower risk in terms of short-term price fluctuations for HTGM.Check VCYT's competition here
CareDx, Inc (NASDAQ: CDNA)
HTGM vs CDNA Comparison September 2026
HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HTGM stands at 1.1M. In comparison, CDNA has a market cap of 3.3B. Regarding current trading prices, HTGM is priced at $0.48 on the NASDAQ, while CDNA trades at $64.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HTGM currently has a P/E ratio of -0.03, whereas CDNA's P/E ratio is 76.21. In terms of profitability, HTGM's ROE is -2.73%, compared to CDNA's ROE of +0.33%. Regarding short-term risk, HTGM is less volatile compared to CDNA. This indicates lower risk in terms of short-term price fluctuations for HTGM.Check CDNA's competition here
Olink Holding AB (publ) (NASDAQ: OLK)
HTGM vs OLK Comparison September 2026
HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HTGM stands at 1.1M. In comparison, OLK has a market cap of 3.2B. Regarding current trading prices, HTGM is priced at $0.48 on the NASDAQ, while OLK trades at $26.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HTGM currently has a P/E ratio of -0.03, whereas OLK's P/E ratio is -96.59. In terms of profitability, HTGM's ROE is -2.73%, compared to OLK's ROE of -0.07%. Regarding short-term risk, HTGM is less volatile compared to OLK. This indicates lower risk in terms of short-term price fluctuations for HTGM.Check OLK's competition here
GeneDx Holdings Corp. (NASDAQ: WGS)
HTGM vs WGS Comparison September 2026
HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HTGM stands at 1.1M. In comparison, WGS has a market cap of 2.3B. Regarding current trading prices, HTGM is priced at $0.48 on the NASDAQ, while WGS trades at $75.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HTGM currently has a P/E ratio of -0.03, whereas WGS's P/E ratio is 210.53. In terms of profitability, HTGM's ROE is -2.73%, compared to WGS's ROE of -0.39%. Regarding short-term risk, HTGM is less volatile compared to WGS. This indicates lower risk in terms of short-term price fluctuations for HTGM.Check WGS's competition here
Personalis, Inc. (NASDAQ: PSNL)
HTGM vs PSNL Comparison September 2026
HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HTGM stands at 1.1M. In comparison, PSNL has a market cap of 1.7B. Regarding current trading prices, HTGM is priced at $0.48 on the NASDAQ, while PSNL trades at $16.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HTGM currently has a P/E ratio of -0.03, whereas PSNL's P/E ratio is -15.00. In terms of profitability, HTGM's ROE is -2.73%, compared to PSNL's ROE of -0.46%. Regarding short-term risk, HTGM is less volatile compared to PSNL. This indicates lower risk in terms of short-term price fluctuations for HTGM.Check PSNL's competition here
OPKO Health, Inc. (NASDAQ: OPK)
HTGM vs OPK Comparison September 2026
HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HTGM stands at 1.1M. In comparison, OPK has a market cap of 1.2B. Regarding current trading prices, HTGM is priced at $0.48 on the NASDAQ, while OPK trades at $1.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HTGM currently has a P/E ratio of -0.03, whereas OPK's P/E ratio is -6.00. In terms of profitability, HTGM's ROE is -2.73%, compared to OPK's ROE of -0.06%. Regarding short-term risk, HTGM is less volatile compared to OPK. This indicates lower risk in terms of short-term price fluctuations for HTGM.Check OPK's competition here
Castle Biosciences, Inc. (NASDAQ: CSTL)
HTGM vs CSTL Comparison September 2026
HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HTGM stands at 1.1M. In comparison, CSTL has a market cap of 1.1B. Regarding current trading prices, HTGM is priced at $0.48 on the NASDAQ, while CSTL trades at $34.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HTGM currently has a P/E ratio of -0.03, whereas CSTL's P/E ratio is -52.85. In terms of profitability, HTGM's ROE is -2.73%, compared to CSTL's ROE of -0.04%. Regarding short-term risk, HTGM is less volatile compared to CSTL. This indicates lower risk in terms of short-term price fluctuations for HTGM.Check CSTL's competition here
Fulgent Genetics, Inc. (NASDAQ: FLGT)
HTGM vs FLGT Comparison September 2026
HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HTGM stands at 1.1M. In comparison, FLGT has a market cap of 627.1M. Regarding current trading prices, HTGM is priced at $0.48 on the NASDAQ, while FLGT trades at $22.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HTGM currently has a P/E ratio of -0.03, whereas FLGT's P/E ratio is 2208.00. In terms of profitability, HTGM's ROE is -2.73%, compared to FLGT's ROE of -0.08%. Regarding short-term risk, HTGM is less volatile compared to FLGT. This indicates lower risk in terms of short-term price fluctuations for HTGM.Check FLGT's competition here
GRAIL, Inc. Common Stock (NASDAQ: GRALV)
HTGM vs GRALV Comparison September 2026
HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HTGM stands at 1.1M. In comparison, GRALV has a market cap of 579.4M. Regarding current trading prices, HTGM is priced at $0.48 on the NASDAQ, while GRALV trades at $18.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HTGM currently has a P/E ratio of -0.03, whereas GRALV's P/E ratio is N/A. In terms of profitability, HTGM's ROE is -2.73%, compared to GRALV's ROE of N/A. Regarding short-term risk, HTGM is less volatile compared to GRALV. This indicates lower risk in terms of short-term price fluctuations for HTGM.Check GRALV's competition here
NeoGenomics, Inc. (NASDAQ: NEO)
HTGM vs NEO Comparison September 2026
HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HTGM stands at 1.1M. In comparison, NEO has a market cap of 481.5M. Regarding current trading prices, HTGM is priced at $0.48 on the NASDAQ, while NEO trades at $18.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HTGM currently has a P/E ratio of -0.03, whereas NEO's P/E ratio is 144.15. In terms of profitability, HTGM's ROE is -2.73%, compared to NEO's ROE of -0.06%. Regarding short-term risk, HTGM is less volatile compared to NEO. This indicates lower risk in terms of short-term price fluctuations for HTGM.Check NEO's competition here
Global Cord Blood Corporation (NYSE: CO)
HTGM vs CO Comparison September 2026
HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HTGM stands at 1.1M. In comparison, CO has a market cap of 400.1M. Regarding current trading prices, HTGM is priced at $0.48 on the NASDAQ, while CO trades at $2.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HTGM currently has a P/E ratio of -0.03, whereas CO's P/E ratio is 5.06. In terms of profitability, HTGM's ROE is -2.73%, compared to CO's ROE of +0.11%. Regarding short-term risk, HTGM is less volatile compared to CO. This indicates lower risk in terms of short-term price fluctuations for HTGM.Check CO's competition here
Myriad Genetics, Inc. (NASDAQ: MYGN)
HTGM vs MYGN Comparison September 2026
HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HTGM stands at 1.1M. In comparison, MYGN has a market cap of 399.5M. Regarding current trading prices, HTGM is priced at $0.48 on the NASDAQ, while MYGN trades at $4.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HTGM currently has a P/E ratio of -0.03, whereas MYGN's P/E ratio is -32.54. In terms of profitability, HTGM's ROE is -2.73%, compared to MYGN's ROE of -0.33%. Regarding short-term risk, HTGM is less volatile compared to MYGN. This indicates lower risk in terms of short-term price fluctuations for HTGM.Check MYGN's competition here
Standard BioTools Inc. (NASDAQ: FLDM)
HTGM vs FLDM Comparison September 2026
HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HTGM stands at 1.1M. In comparison, FLDM has a market cap of 294.2M. Regarding current trading prices, HTGM is priced at $0.48 on the NASDAQ, while FLDM trades at $3.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HTGM currently has a P/E ratio of -0.03, whereas FLDM's P/E ratio is -4.74. In terms of profitability, HTGM's ROE is -2.73%, compared to FLDM's ROE of +0.18%. Regarding short-term risk, HTGM is less volatile compared to FLDM. This indicates lower risk in terms of short-term price fluctuations for HTGM.Check FLDM's competition here
Biodesix, Inc. (NASDAQ: BDSX)
HTGM vs BDSX Comparison September 2026
HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HTGM stands at 1.1M. In comparison, BDSX has a market cap of 237.2M. Regarding current trading prices, HTGM is priced at $0.48 on the NASDAQ, while BDSX trades at $29.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HTGM currently has a P/E ratio of -0.03, whereas BDSX's P/E ratio is -9.19. In terms of profitability, HTGM's ROE is -2.73%, compared to BDSX's ROE of -7.88%. Regarding short-term risk, HTGM is less volatile compared to BDSX. This indicates lower risk in terms of short-term price fluctuations for HTGM.Check BDSX's competition here
Exagen Inc. (NASDAQ: XGN)
HTGM vs XGN Comparison September 2026
HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HTGM stands at 1.1M. In comparison, XGN has a market cap of 204.9M. Regarding current trading prices, HTGM is priced at $0.48 on the NASDAQ, while XGN trades at $8.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HTGM currently has a P/E ratio of -0.03, whereas XGN's P/E ratio is -10.47. In terms of profitability, HTGM's ROE is -2.73%, compared to XGN's ROE of -1.22%. Regarding short-term risk, HTGM is less volatile compared to XGN. This indicates lower risk in terms of short-term price fluctuations for HTGM.Check XGN's competition here
Freenome, Inc. (NASDAQ: FRNM)
HTGM vs FRNM Comparison September 2026
HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HTGM stands at 1.1M. In comparison, FRNM has a market cap of 129.9M. Regarding current trading prices, HTGM is priced at $0.48 on the NASDAQ, while FRNM trades at $15.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HTGM currently has a P/E ratio of -0.03, whereas FRNM's P/E ratio is N/A. In terms of profitability, HTGM's ROE is -2.73%, compared to FRNM's ROE of N/A. Regarding short-term risk, HTGM is less volatile compared to FRNM. This indicates lower risk in terms of short-term price fluctuations for HTGM.Check FRNM's competition here
Genetron Holdings Limited (NASDAQ: GTH)
HTGM vs GTH Comparison September 2026
HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HTGM stands at 1.1M. In comparison, GTH has a market cap of 127.3M. Regarding current trading prices, HTGM is priced at $0.48 on the NASDAQ, while GTH trades at $4.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HTGM currently has a P/E ratio of -0.03, whereas GTH's P/E ratio is -1.11. In terms of profitability, HTGM's ROE is -2.73%, compared to GTH's ROE of -1.01%. Regarding short-term risk, HTGM is less volatile compared to GTH. This indicates lower risk in terms of short-term price fluctuations for HTGM.Check GTH's competition here
Genetic Technologies Limited (NASDAQ: GENE)
HTGM vs GENE Comparison September 2026
HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HTGM stands at 1.1M. In comparison, GENE has a market cap of 111.2M. Regarding current trading prices, HTGM is priced at $0.48 on the NASDAQ, while GENE trades at $0.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HTGM currently has a P/E ratio of -0.03, whereas GENE's P/E ratio is -38.25. In terms of profitability, HTGM's ROE is -2.73%, compared to GENE's ROE of -1.85%. Regarding short-term risk, HTGM is similarly volatile compared to GENE. This indicates similar risk in terms of short-term price fluctuations for HTGM.Check GENE's competition here
Insight Molecular Diagnostics Inc. (NASDAQ: IMDX)
HTGM vs IMDX Comparison September 2026
HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HTGM stands at 1.1M. In comparison, IMDX has a market cap of 109.1M. Regarding current trading prices, HTGM is priced at $0.48 on the NASDAQ, while IMDX trades at $3.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HTGM currently has a P/E ratio of -0.03, whereas IMDX's P/E ratio is -2.27. In terms of profitability, HTGM's ROE is -2.73%, compared to IMDX's ROE of +2.72%. Regarding short-term risk, HTGM is less volatile compared to IMDX. This indicates lower risk in terms of short-term price fluctuations for HTGM.Check IMDX's competition here
Sera Prognostics, Inc. (NASDAQ: SERA)
HTGM vs SERA Comparison September 2026
HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HTGM stands at 1.1M. In comparison, SERA has a market cap of 78.3M. Regarding current trading prices, HTGM is priced at $0.48 on the NASDAQ, while SERA trades at $2.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HTGM currently has a P/E ratio of -0.03, whereas SERA's P/E ratio is -3.15. In terms of profitability, HTGM's ROE is -2.73%, compared to SERA's ROE of -0.47%. Regarding short-term risk, HTGM is less volatile compared to SERA. This indicates lower risk in terms of short-term price fluctuations for HTGM.Check SERA's competition here
Precipio, Inc. (NASDAQ: PRPO)
HTGM vs PRPO Comparison September 2026
HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HTGM stands at 1.1M. In comparison, PRPO has a market cap of 42.1M. Regarding current trading prices, HTGM is priced at $0.48 on the NASDAQ, while PRPO trades at $23.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HTGM currently has a P/E ratio of -0.03, whereas PRPO's P/E ratio is -36.28. In terms of profitability, HTGM's ROE is -2.73%, compared to PRPO's ROE of -0.08%. Regarding short-term risk, HTGM is less volatile compared to PRPO. This indicates lower risk in terms of short-term price fluctuations for HTGM.Check PRPO's competition here
Quantum Cyber N.V. (NASDAQ: QUCY)
HTGM vs QUCY Comparison September 2026
HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HTGM stands at 1.1M. In comparison, QUCY has a market cap of 29.4M. Regarding current trading prices, HTGM is priced at $0.48 on the NASDAQ, while QUCY trades at $1.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HTGM currently has a P/E ratio of -0.03, whereas QUCY's P/E ratio is -0.06. In terms of profitability, HTGM's ROE is -2.73%, compared to QUCY's ROE of -3.65%. Regarding short-term risk, HTGM is less volatile compared to QUCY. This indicates lower risk in terms of short-term price fluctuations for HTGM.Check QUCY's competition here
MDxHealth S.A. (NASDAQ: MDXH)
HTGM vs MDXH Comparison September 2026
HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HTGM stands at 1.1M. In comparison, MDXH has a market cap of 26.7M. Regarding current trading prices, HTGM is priced at $0.48 on the NASDAQ, while MDXH trades at $0.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HTGM currently has a P/E ratio of -0.03, whereas MDXH's P/E ratio is -0.71. In terms of profitability, HTGM's ROE is -2.73%, compared to MDXH's ROE of +1.43%. Regarding short-term risk, HTGM is less volatile compared to MDXH. This indicates lower risk in terms of short-term price fluctuations for HTGM.Check MDXH's competition here
Akumin Inc. (NASDAQ: AKU)
HTGM vs AKU Comparison September 2026
HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HTGM stands at 1.1M. In comparison, AKU has a market cap of 26.3M. Regarding current trading prices, HTGM is priced at $0.48 on the NASDAQ, while AKU trades at $0.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HTGM currently has a P/E ratio of -0.03, whereas AKU's P/E ratio is -0.13. In terms of profitability, HTGM's ROE is -2.73%, compared to AKU's ROE of -5.32%. Regarding short-term risk, HTGM is less volatile compared to AKU. This indicates lower risk in terms of short-term price fluctuations for HTGM.Check AKU's competition here
Burning Rock Biotech Limited (NASDAQ: BNR)
HTGM vs BNR Comparison September 2026
HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HTGM stands at 1.1M. In comparison, BNR has a market cap of 20M. Regarding current trading prices, HTGM is priced at $0.48 on the NASDAQ, while BNR trades at $18.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HTGM currently has a P/E ratio of -0.03, whereas BNR's P/E ratio is -21.77. In terms of profitability, HTGM's ROE is -2.73%, compared to BNR's ROE of -0.13%. Regarding short-term risk, HTGM is less volatile compared to BNR. This indicates lower risk in terms of short-term price fluctuations for HTGM.Check BNR's competition here
Chembio Diagnostics, Inc. (NASDAQ: CEMI)
HTGM vs CEMI Comparison September 2026
HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HTGM stands at 1.1M. In comparison, CEMI has a market cap of 16.7M. Regarding current trading prices, HTGM is priced at $0.48 on the NASDAQ, while CEMI trades at $0.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HTGM currently has a P/E ratio of -0.03, whereas CEMI's P/E ratio is -0.63. In terms of profitability, HTGM's ROE is -2.73%, compared to CEMI's ROE of -0.89%. Regarding short-term risk, HTGM is similarly volatile compared to CEMI. This indicates similar risk in terms of short-term price fluctuations for HTGM.Check CEMI's competition here
Enzo Biochem, Inc. (NYSE: ENZ)
HTGM vs ENZ Comparison September 2026
HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HTGM stands at 1.1M. In comparison, ENZ has a market cap of 16.4M. Regarding current trading prices, HTGM is priced at $0.48 on the NASDAQ, while ENZ trades at $0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HTGM currently has a P/E ratio of -0.03, whereas ENZ's P/E ratio is -2.24. In terms of profitability, HTGM's ROE is -2.73%, compared to ENZ's ROE of -0.39%. Regarding short-term risk, HTGM is less volatile compared to ENZ. This indicates lower risk in terms of short-term price fluctuations for HTGM.Check ENZ's competition here
Psychemedics Corporation (NASDAQ: PMD)
HTGM vs PMD Comparison September 2026
HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HTGM stands at 1.1M. In comparison, PMD has a market cap of 15.6M. Regarding current trading prices, HTGM is priced at $0.48 on the NASDAQ, while PMD trades at $2.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HTGM currently has a P/E ratio of -0.03, whereas PMD's P/E ratio is -5.24. In terms of profitability, HTGM's ROE is -2.73%, compared to PMD's ROE of -0.32%. Regarding short-term risk, HTGM is similarly volatile compared to PMD. This indicates similar risk in terms of short-term price fluctuations for HTGM.Check PMD's competition here
23andMe Holding Co. (NASDAQ: ME)
HTGM vs ME Comparison September 2026
HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HTGM stands at 1.1M. In comparison, ME has a market cap of 15.3M. Regarding current trading prices, HTGM is priced at $0.48 on the NASDAQ, while ME trades at $0.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HTGM currently has a P/E ratio of -0.03, whereas ME's P/E ratio is -0.03. In terms of profitability, HTGM's ROE is -2.73%, compared to ME's ROE of -42.03%. Regarding short-term risk, HTGM is similarly volatile compared to ME. This indicates similar risk in terms of short-term price fluctuations for HTGM.Check ME's competition here
Mainz Biomed B.V. (NASDAQ: MYNZ)
HTGM vs MYNZ Comparison September 2026
HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HTGM stands at 1.1M. In comparison, MYNZ has a market cap of 14.7M. Regarding current trading prices, HTGM is priced at $0.48 on the NASDAQ, while MYNZ trades at $3.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HTGM currently has a P/E ratio of -0.03, whereas MYNZ's P/E ratio is -0.68. In terms of profitability, HTGM's ROE is -2.73%, compared to MYNZ's ROE of -1.80%. Regarding short-term risk, HTGM is less volatile compared to MYNZ. This indicates lower risk in terms of short-term price fluctuations for HTGM.Check MYNZ's competition here
bioAffinity Technologies, Inc. (NASDAQ: BIAFW)
HTGM vs BIAFW Comparison September 2026
HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HTGM stands at 1.1M. In comparison, BIAFW has a market cap of 11.4M. Regarding current trading prices, HTGM is priced at $0.48 on the NASDAQ, while BIAFW trades at $0.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HTGM currently has a P/E ratio of -0.03, whereas BIAFW's P/E ratio is 1.21. In terms of profitability, HTGM's ROE is -2.73%, compared to BIAFW's ROE of -2.57%. Regarding short-term risk, HTGM is less volatile compared to BIAFW. This indicates lower risk in terms of short-term price fluctuations for HTGM.Check BIAFW's competition here
Check-Cap Ltd. (NASDAQ: CHEK)
HTGM vs CHEK Comparison September 2026
HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HTGM stands at 1.1M. In comparison, CHEK has a market cap of 10.9M. Regarding current trading prices, HTGM is priced at $0.48 on the NASDAQ, while CHEK trades at $1.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HTGM currently has a P/E ratio of -0.03, whereas CHEK's P/E ratio is -0.43. In terms of profitability, HTGM's ROE is -2.73%, compared to CHEK's ROE of -2.26%. Regarding short-term risk, HTGM is less volatile compared to CHEK. This indicates lower risk in terms of short-term price fluctuations for HTGM.Check CHEK's competition here
Centogene N.V. (NASDAQ: CNTG)
HTGM vs CNTG Comparison September 2026
HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HTGM stands at 1.1M. In comparison, CNTG has a market cap of 9.4M. Regarding current trading prices, HTGM is priced at $0.48 on the NASDAQ, while CNTG trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HTGM currently has a P/E ratio of -0.03, whereas CNTG's P/E ratio is -0.23. In terms of profitability, HTGM's ROE is -2.73%, compared to CNTG's ROE of +3.98%. Regarding short-term risk, HTGM is similarly volatile compared to CNTG. This indicates similar risk in terms of short-term price fluctuations for HTGM.Check CNTG's competition here
Advanced Biomed Inc. Common Stock (NASDAQ: ADVB)
HTGM vs ADVB Comparison September 2026
HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HTGM stands at 1.1M. In comparison, ADVB has a market cap of 8.7M. Regarding current trading prices, HTGM is priced at $0.48 on the NASDAQ, while ADVB trades at $6.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HTGM currently has a P/E ratio of -0.03, whereas ADVB's P/E ratio is -57.45. In terms of profitability, HTGM's ROE is -2.73%, compared to ADVB's ROE of -0.21%. Regarding short-term risk, HTGM is less volatile compared to ADVB. This indicates lower risk in terms of short-term price fluctuations for HTGM.Check ADVB's competition here
ENDRA Life Sciences Inc. (NASDAQ: NDRA)
HTGM vs NDRA Comparison September 2026
HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HTGM stands at 1.1M. In comparison, NDRA has a market cap of 7.5M. Regarding current trading prices, HTGM is priced at $0.48 on the NASDAQ, while NDRA trades at $5.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HTGM currently has a P/E ratio of -0.03, whereas NDRA's P/E ratio is -0.88. In terms of profitability, HTGM's ROE is -2.73%, compared to NDRA's ROE of -2.25%. Regarding short-term risk, HTGM is less volatile compared to NDRA. This indicates lower risk in terms of short-term price fluctuations for HTGM.Check NDRA's competition here
Applied DNA Sciences, Inc. (NASDAQ: APDN)
HTGM vs APDN Comparison September 2026
HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HTGM stands at 1.1M. In comparison, APDN has a market cap of 7.3M. Regarding current trading prices, HTGM is priced at $0.48 on the NASDAQ, while APDN trades at $5.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HTGM currently has a P/E ratio of -0.03, whereas APDN's P/E ratio is -0.10. In terms of profitability, HTGM's ROE is -2.73%, compared to APDN's ROE of -7.23%. Regarding short-term risk, HTGM is less volatile compared to APDN. This indicates lower risk in terms of short-term price fluctuations for HTGM.Check APDN's competition here
Invitae Corporation (NYSE: NVTA)
HTGM vs NVTA Comparison September 2026
HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HTGM stands at 1.1M. In comparison, NVTA has a market cap of 5.4M. Regarding current trading prices, HTGM is priced at $0.48 on the NASDAQ, while NVTA trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HTGM currently has a P/E ratio of -0.03, whereas NVTA's P/E ratio is -0.00. In terms of profitability, HTGM's ROE is -2.73%, compared to NVTA's ROE of -2.02%. Regarding short-term risk, HTGM is less volatile compared to NVTA. This indicates lower risk in terms of short-term price fluctuations for HTGM.Check NVTA's competition here
LumiraDx Limited (NASDAQ: LMDXW)
HTGM vs LMDXW Comparison September 2026
HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HTGM stands at 1.1M. In comparison, LMDXW has a market cap of 5.1M. Regarding current trading prices, HTGM is priced at $0.48 on the NASDAQ, while LMDXW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HTGM currently has a P/E ratio of -0.03, whereas LMDXW's P/E ratio is -0.00. In terms of profitability, HTGM's ROE is -2.73%, compared to LMDXW's ROE of -15.58%. Regarding short-term risk, HTGM is less volatile compared to LMDXW. This indicates lower risk in terms of short-term price fluctuations for HTGM.Check LMDXW's competition here
LumiraDx Limited (NASDAQ: LMDX)
HTGM vs LMDX Comparison September 2026
HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HTGM stands at 1.1M. In comparison, LMDX has a market cap of 5.1M. Regarding current trading prices, HTGM is priced at $0.48 on the NASDAQ, while LMDX trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HTGM currently has a P/E ratio of -0.03, whereas LMDX's P/E ratio is -0.01. In terms of profitability, HTGM's ROE is -2.73%, compared to LMDX's ROE of -15.58%. Regarding short-term risk, HTGM is less volatile compared to LMDX. This indicates lower risk in terms of short-term price fluctuations for HTGM.Check LMDX's competition here
DermTech, Inc. (NASDAQ: DMTK)
HTGM vs DMTK Comparison September 2026
HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HTGM stands at 1.1M. In comparison, DMTK has a market cap of 3.3M. Regarding current trading prices, HTGM is priced at $0.48 on the NASDAQ, while DMTK trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HTGM currently has a P/E ratio of -0.03, whereas DMTK's P/E ratio is -0.04. In terms of profitability, HTGM's ROE is -2.73%, compared to DMTK's ROE of -1.06%. Regarding short-term risk, HTGM is less volatile compared to DMTK. This indicates lower risk in terms of short-term price fluctuations for HTGM.Check DMTK's competition here
iSpecimen Inc. (NASDAQ: ISPC)
HTGM vs ISPC Comparison September 2026
HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HTGM stands at 1.1M. In comparison, ISPC has a market cap of 3M. Regarding current trading prices, HTGM is priced at $0.48 on the NASDAQ, while ISPC trades at $1.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HTGM currently has a P/E ratio of -0.03, whereas ISPC's P/E ratio is -0.04. In terms of profitability, HTGM's ROE is -2.73%, compared to ISPC's ROE of -5.24%. Regarding short-term risk, HTGM is less volatile compared to ISPC. This indicates lower risk in terms of short-term price fluctuations for HTGM.Check ISPC's competition here
bioAffinity Technologies, Inc. (NASDAQ: BIAF)
HTGM vs BIAF Comparison September 2026
HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HTGM stands at 1.1M. In comparison, BIAF has a market cap of 2.9M. Regarding current trading prices, HTGM is priced at $0.48 on the NASDAQ, while BIAF trades at $6.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HTGM currently has a P/E ratio of -0.03, whereas BIAF's P/E ratio is -0.81. In terms of profitability, HTGM's ROE is -2.73%, compared to BIAF's ROE of -2.57%. Regarding short-term risk, HTGM is less volatile compared to BIAF. This indicates lower risk in terms of short-term price fluctuations for HTGM.Check BIAF's competition here
Inotiv, Inc. (NASDAQ: NOTV)
HTGM vs NOTV Comparison September 2026
HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HTGM stands at 1.1M. In comparison, NOTV has a market cap of 2.8M. Regarding current trading prices, HTGM is priced at $0.48 on the NASDAQ, while NOTV trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HTGM currently has a P/E ratio of -0.03, whereas NOTV's P/E ratio is -0.03. In terms of profitability, HTGM's ROE is -2.73%, compared to NOTV's ROE of -0.75%. Regarding short-term risk, HTGM is less volatile compared to NOTV. This indicates lower risk in terms of short-term price fluctuations for HTGM.Check NOTV's competition here
SeqLL Inc. (NASDAQ: SQL)
HTGM vs SQL Comparison September 2026
HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HTGM stands at 1.1M. In comparison, SQL has a market cap of 2.5M. Regarding current trading prices, HTGM is priced at $0.48 on the NASDAQ, while SQL trades at $6.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HTGM currently has a P/E ratio of -0.03, whereas SQL's P/E ratio is -0.40. In terms of profitability, HTGM's ROE is -2.73%, compared to SQL's ROE of -30.46%. Regarding short-term risk, HTGM is less volatile compared to SQL. This indicates lower risk in terms of short-term price fluctuations for HTGM.Check SQL's competition here
Aspira Women's Health Inc. (NASDAQ: AWH)
HTGM vs AWH Comparison September 2026
HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HTGM stands at 1.1M. In comparison, AWH has a market cap of 2.5M. Regarding current trading prices, HTGM is priced at $0.48 on the NASDAQ, while AWH trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HTGM currently has a P/E ratio of -0.03, whereas AWH's P/E ratio is -0.09. In terms of profitability, HTGM's ROE is -2.73%, compared to AWH's ROE of +1.62%. Regarding short-term risk, HTGM is similarly volatile compared to AWH. This indicates similar risk in terms of short-term price fluctuations for HTGM.Check AWH's competition here
Biocept, Inc. (NASDAQ: BIOC)
HTGM vs BIOC Comparison September 2026
HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HTGM stands at 1.1M. In comparison, BIOC has a market cap of 450.8K. Regarding current trading prices, HTGM is priced at $0.48 on the NASDAQ, while BIOC trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HTGM currently has a P/E ratio of -0.03, whereas BIOC's P/E ratio is -0.01. In terms of profitability, HTGM's ROE is -2.73%, compared to BIOC's ROE of -1.38%. Regarding short-term risk, HTGM is less volatile compared to BIOC. This indicates lower risk in terms of short-term price fluctuations for HTGM.Check BIOC's competition here
SeqLL Inc. (NASDAQ: SQLLW)
HTGM vs SQLLW Comparison September 2026
HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HTGM stands at 1.1M. In comparison, SQLLW has a market cap of 179.6K. Regarding current trading prices, HTGM is priced at $0.48 on the NASDAQ, while SQLLW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HTGM currently has a P/E ratio of -0.03, whereas SQLLW's P/E ratio is -0.00. In terms of profitability, HTGM's ROE is -2.73%, compared to SQLLW's ROE of -30.46%. Regarding short-term risk, HTGM is less volatile compared to SQLLW. This indicates lower risk in terms of short-term price fluctuations for HTGM.Check SQLLW's competition here
GeneDx Holdings Corp. (NASDAQ: WGSWW)
HTGM vs WGSWW Comparison September 2026
HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HTGM stands at 1.1M. In comparison, WGSWW has a market cap of 5.8K. Regarding current trading prices, HTGM is priced at $0.48 on the NASDAQ, while WGSWW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HTGM currently has a P/E ratio of -0.03, whereas WGSWW's P/E ratio is -0.00. In terms of profitability, HTGM's ROE is -2.73%, compared to WGSWW's ROE of -0.39%. Regarding short-term risk, HTGM is similarly volatile compared to WGSWW. This indicates similar risk in terms of short-term price fluctuations for HTGM.Check WGSWW's competition here
23andMe Holding Co. (NASDAQ: MEUSW)
HTGM vs MEUSW Comparison September 2026
HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HTGM stands at 1.1M. In comparison, MEUSW has a market cap of 0. Regarding current trading prices, HTGM is priced at $0.48 on the NASDAQ, while MEUSW trades at $1.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HTGM currently has a P/E ratio of -0.03, whereas MEUSW's P/E ratio is N/A. In terms of profitability, HTGM's ROE is -2.73%, compared to MEUSW's ROE of -42.03%. Regarding short-term risk, HTGM is less volatile compared to MEUSW. This indicates lower risk in terms of short-term price fluctuations for HTGM.Check MEUSW's competition here
PAREXEL Intl Corp. (NASDAQ: PRXL)
HTGM vs PRXL Comparison September 2026
HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HTGM stands at 1.1M. In comparison, PRXL has a market cap of 0. Regarding current trading prices, HTGM is priced at $0.48 on the NASDAQ, while PRXL trades at $88.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HTGM currently has a P/E ratio of -0.03, whereas PRXL's P/E ratio is 42.97. In terms of profitability, HTGM's ROE is -2.73%, compared to PRXL's ROE of +0.17%. Regarding short-term risk, HTGM is less volatile compared to PRXL. This indicates lower risk in terms of short-term price fluctuations for HTGM.Check PRXL's competition here
Ortho Clinical Diagnostics Holdings plc (NASDAQ: OCDX)
HTGM vs OCDX Comparison September 2026
HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HTGM stands at 1.1M. In comparison, OCDX has a market cap of 0. Regarding current trading prices, HTGM is priced at $0.48 on the NASDAQ, while OCDX trades at $17.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HTGM currently has a P/E ratio of -0.03, whereas OCDX's P/E ratio is -42.28. In terms of profitability, HTGM's ROE is -2.73%, compared to OCDX's ROE of +0.18%. Regarding short-term risk, HTGM is less volatile compared to OCDX. This indicates lower risk in terms of short-term price fluctuations for HTGM.Check OCDX's competition here
Danaher Corporation (NYSE: DHR-PA)
HTGM vs DHR-PA Comparison September 2026
HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HTGM stands at 1.1M. In comparison, DHR-PA has a market cap of 0. Regarding current trading prices, HTGM is priced at $0.48 on the NASDAQ, while DHR-PA trades at $1,841.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HTGM currently has a P/E ratio of -0.03, whereas DHR-PA's P/E ratio is 233.57. In terms of profitability, HTGM's ROE is -2.73%, compared to DHR-PA's ROE of +0.08%. Regarding short-term risk, HTGM is less volatile compared to DHR-PA. This indicates lower risk in terms of short-term price fluctuations for HTGM.Check DHR-PA's competition here
BioNano Genomics, Inc. WT EXP 082123 (NASDAQ: BNGOW)
HTGM vs BNGOW Comparison September 2026
HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HTGM stands at 1.1M. In comparison, BNGOW has a market cap of 0. Regarding current trading prices, HTGM is priced at $0.48 on the NASDAQ, while BNGOW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HTGM currently has a P/E ratio of -0.03, whereas BNGOW's P/E ratio is N/A. In terms of profitability, HTGM's ROE is -2.73%, compared to BNGOW's ROE of -0.79%. Regarding short-term risk, HTGM is less volatile compared to BNGOW. This indicates lower risk in terms of short-term price fluctuations for HTGM.Check BNGOW's competition here
ENDRA Life Sciences Inc. Warrants (NASDAQ: NDRAW)
HTGM vs NDRAW Comparison September 2026
HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HTGM stands at 1.1M. In comparison, NDRAW has a market cap of 0. Regarding current trading prices, HTGM is priced at $0.48 on the NASDAQ, while NDRAW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HTGM currently has a P/E ratio of -0.03, whereas NDRAW's P/E ratio is N/A. In terms of profitability, HTGM's ROE is -2.73%, compared to NDRAW's ROE of -2.25%. Regarding short-term risk, HTGM is less volatile compared to NDRAW. This indicates lower risk in terms of short-term price fluctuations for HTGM.Check NDRAW's competition here
Check-Cap Ltd (NASDAQ: CHEKZ)
HTGM vs CHEKZ Comparison September 2026
HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HTGM stands at 1.1M. In comparison, CHEKZ has a market cap of 0. Regarding current trading prices, HTGM is priced at $0.48 on the NASDAQ, while CHEKZ trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HTGM currently has a P/E ratio of -0.03, whereas CHEKZ's P/E ratio is N/A. In terms of profitability, HTGM's ROE is -2.73%, compared to CHEKZ's ROE of +4.17%. Regarding short-term risk, HTGM is less volatile compared to CHEKZ. This indicates lower risk in terms of short-term price fluctuations for HTGM.Check CHEKZ's competition here